Epicore BioNetworks Inc. (V:EBN)
Business Focus: N/A
Dec 18, 2017 03:30 pm ET
Epicore BioNetworks Inc. and Neovia S.A.S. jointly announce completion of an arrangement involving Epicore, its security holders and Neovia Probiotics Inc. ("Neovia"), a wholly owned subsidiary of Neo
EASTAMPTON, NJ, Dec. 18, 2017 /CNW/ - Epicore BioNetworks Inc. ("Epicore") (TSXV EBN) and Neovia S.A.S. are pleased to announce the completion of the previously announced plan of arrangement ("Arrangement") involving Epicore, its security holders and Neovia. Pursuant to the Arrangement, Neovia has acquired all of the issued and outstanding shares of Epicore effective December 18, 2017. The shares of Epicore have been delisted from the TSX Venture Exchange.
Dec 15, 2017 04:10 pm ET
IIROC Trade Halt - Epicore BioNetworks Inc.
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2017) - The following issues have been halted by IIROC:
Dec 15, 2017 03:27 pm ET
IIROC Trading Halt - EBN
VANCOUVER, Dec. 15, 2017 /CNW/ - The following issues have been halted by IIROC:
Dec 13, 2017 03:30 pm ET
Shareholders of Epicore BioNetworks Inc. Overwhelmingly Approve Proposed Transaction with Neovia Probiotics Inc. ("Neovia"), a wholly owned subsidiary of Neovia S.A.S.
EASTAMPTON, NJ, Dec. 13, 2017 /PRNewswire/ - Epicore BioNetworks Inc. ("Epicore") (TSXV EBN) and Neovia S.A.S. are pleased to announce that shareholders of Epicore have overwhelmingly approved the plan of arrangement ("Arrangement") with Neovia at the special meeting of shareholders held earlier today. Pursuant to the Arrangement, Neovia will acquire all of the issued and outstanding shares of Epicore on a fully‑diluted basis. The Arrangement is expected to be completed on December 18, 2017.
Dec 13, 2017 03:30 pm ET
Shareholders of Epicore BioNetworks Inc. Overwhelmingly Approve Proposed Transaction with Neovia Probiotics Inc. ("Neovia"), a wholly owned subsidiary of Neovia S.A.S.
EASTAMPTON, NJ, Dec. 13, 2017 /CNW/ - Epicore BioNetworks Inc. ("Epicore") (TSXV EBN) and Neovia S.A.S. are pleased to announce that shareholders of Epicore have overwhelmingly approved the plan of arrangement ("Arrangement") with Neovia at the special meeting of shareholders held earlier today. Pursuant to the Arrangement, Neovia will acquire all of the issued and outstanding shares of Epicore on a fully‑diluted basis. The Arrangement is expected to be completed on December 18, 2017.
Nov 16, 2017 04:30 pm ET
Epicore BioNetworks Inc. Reports Results for Q1 Fiscal Year 2018 for the quarter ended 30 September 2017, in US dollars
EASTAMPTON, NJ, Nov. 16, 2017 /CNW/ - Revenue for Q1 at $2.8 million was 15% higher than last year's Q1, setting a new Q1 sales record. Sales increases were achieved in several areas. Sales were especially strong in Ecuador, Venezuela, Africa, and Australia. Overall, the rest of Latin America maintained the strong level of sales achieved in fiscal 2017 because of strong sales to Venezuela. Sales to Asia were close to fiscal 2017 level. The early mortality syndrome (EMS) disease continues to significantly affect production in Asia and Mexico and has been found in other Latin American coun
Nov 16, 2017 04:30 pm ET
Epicore BioNetworks Inc. Reports Results for Q1 Fiscal Year 2018 for the quarter ended 30 September 2017, in US dollars
EASTAMPTON, NJ, Nov. 16, 2017 /PRNewswire/ - Revenue for Q1 at $2.8 million was 15% higher than last year's Q1, setting a new Q1 sales record. Sales increases were achieved in several areas. Sales were especially strong in Ecuador, Venezuela, Africa, and Australia. Overall, the rest of Latin America maintained the strong level of sales achieved in fiscal 2017 because of strong sales to Venezuela. Sales to Asia were close to fiscal 2017 level. The early mortality syndrome (EMS) disease continues to significantly affect production in Asia and Mexico and has been found in other Latin Americ
Oct 16, 2017 09:00 am ET
Neovia S.A.S. to Acquire Epicore BioNetworks Inc.
EASTAMPTON, NJ, Oct. 16, 2017 /PRNewswire/ - Epicore BioNetworks Inc.("Epicore") (TSXV EBN) and Neovia S.A.S. ("Neovia") jointly announced today that Epicore and Neovia have entered into an arrangement agreement dated October 13, 2017 (Arrangement Agreement") pursuant to which Neovia will acquire all of the issued and outstanding shares of Epicore on a fully-diluted basis for a price per share of Cdn$1.30, valuing Epicore at approximately Cdn$ 35.6million. The purchase price represents a premium to the closing trading price of the Epicore shares prior to this announcement of 25%. The propose
Oct 16, 2017 09:00 am ET
Neovia S.A.S. to Acquire Epicore BioNetworks Inc.
EASTAMPTON, NJ, Oct. 16, 2017 /CNW/ - Epicore BioNetworks Inc.("Epicore") (TSXV EBN) and Neovia S.A.S. ("Neovia") jointly announced today that Epicore and Neovia have entered into an arrangement agreement dated October 13, 2017 (Arrangement Agreement") pursuant to which Neovia will acquire all of the issued and outstanding shares of Epicore on a fully-diluted basis for a price per share of Cdn$1.30, valuing Epicore at approximately Cdn$ 35.6million. The purchase price represents a premium to the closing trading price of the Epicore shares prior to this announcement of 25%. The proposed trans
Oct 11, 2017 05:30 pm ET
Epicore BioNetworks Inc. Reports Results for Fiscal Year 2017 for the Year Ended 30 June 2017, in US Dollars
EASTAMPTON, NJ, Oct. 11, 2017 /PRNewswire/ - Epicore revenue for fiscal 2017 at $11.5 million was 21% higher than prior year. Sales increases were broad based. Latin America was the largest sales region but the recovery in Asia was very strong. Newer areas made a very strong contribution. The shrimp industry recovery began in Q3 of fiscal 2016 as shrimp prices began and continue to slowly increase. The early mortality syndrome (EMS) disease continues to significantly affect production in Asia and Mexico and has been found in other Latin American countries. With higher shrimp prices farme
Oct 11, 2017 05:30 pm ET
Epicore BioNetworks Inc. Reports Results for Fiscal Year 2017 for the Year Ended 30 June 2017, in US Dollars
EASTAMPTON, NJ, Oct. 11, 2017 /CNW/ - Epicore revenue for fiscal 2017 at $11.5 million was 21% higher than prior year. Sales increases were broad based. Latin America was the largest sales region but the recovery in Asia was very strong. Newer areas made a very strong contribution. The shrimp industry recovery began in Q3 of fiscal 2016 as shrimp prices began and continue to slowly increase. The early mortality syndrome (EMS) disease continues to significantly affect production in Asia and Mexico and has been found in other Latin American countries. With higher shrimp prices farmers are
Jul 27, 2017 07:00 pm ET
Epicore BioNetworks Inc. Releases Preliminary Quarter 4 Results for Fiscal Year 2017
for the Quarter ended 30 June 2017, in US dollars
Jul 27, 2017 07:00 pm ET
Epicore BioNetworks Inc. Releases Preliminary Quarter 4 Results for Fiscal Year 2017
for the Quarter ended 30 June 2017, in US dollars
May 17, 2017 05:30 pm ET
Epicore BioNetworks Inc. Reports Quarter Three Results for Fiscal Year 2017 for the Quarter ended 31 March 2017, in US dollars
EASTAMPTON, NJ, May 17, 2017 /PRNewswire/ - Epicore BioNetworks Inc. (TSXV EBN) reported third quarter revenue of $3.0 million and net income of $0.4 million or $0.015 per share for the period ended March 31, 2017.
May 17, 2017 05:30 pm ET
Epicore BioNetworks Inc. Reports Quarter Three Results for Fiscal Year 2017 for the Quarter ended 31 March 2017, in US dollars
EASTAMPTON, NJ, May 17, 2017 /CNW/ - Epicore BioNetworks Inc. (TSXV EBN) reported third quarter revenue of $3.0 million and net income of $0.4 million or $0.015 per share for the period ended March 31, 2017.
Mar 21, 2017 10:30 am ET
Epicore Grants Stock Options
EASTAMPTON, NJ, March 21, 2017 /PRNewswire/ - Epicore BioNetworks Inc. announces that it has granted stock options to non-executive directors, officers and to employees of the company. The number of options granted is 600,000, which is equivalent to 1.1% of Epicore's issued common stock. Of these options, 325,000 were issued to directors and officers. Under the terms of the Epicore Stock Option Plan, options may be issued from time to time in any amount up to a maximum of 7,599,241 Epicore common shares. After issuance of these grants 2,945,913 options are outstanding. These options have
Mar 21, 2017 10:30 am ET
Epicore Grants Stock Options
EASTAMPTON, NJ, March 21, 2017 /CNW/ - Epicore BioNetworks Inc. announces that it has granted stock options to non-executive directors, officers and to employees of the company. The number of options granted is 600,000, which is equivalent to 1.1% of Epicore's issued common stock. Of these options, 325,000 were issued to directors and officers. Under the terms of the Epicore Stock Option Plan, options may be issued from time to time in any amount up to a maximum of 7,599,241 Epicore common shares. After issuance of these grants 2,945,913 options are outstanding. These options have an exer
Mar 15, 2017 05:30 pm ET
Epicore BioNetworks Inc. Reports New Product Offering
EASTAMPTON, NJ, March 15, 2017 /PRNewswire/ - Epicore BioNetworks Inc. (TSXV EBN) reported closing a new arrangement that expands Epicore's line and delivers to shrimp hatcheries an alternative to the challenging practice of growing live algae.
Mar 15, 2017 05:30 pm ET
Epicore BioNetworks Inc. Reports New Product Offering
EASTAMPTON, NJ, March 15, 2017 /CNW/ - Epicore BioNetworks Inc. (TSXV EBN) reported closing a new arrangement that expands Epicore's line and delivers to shrimp hatcheries an alternative to the challenging practice of growing live algae.
Feb 14, 2017 04:30 pm ET
Epicore BioNetworks Inc. Reports Quarter Two Results for Fiscal Year 2017
for the Quarter ended 31 December 2016, in US dollars
Feb 14, 2017 04:30 pm ET
Epicore BioNetworks Inc. Reports Quarter Two Results for Fiscal Year 2017
for the Quarter ended 31 December 2016, in US dollars
Nov 30, 2016 04:30 pm ET
Nov 30, 2016 04:30 pm ET
Epicore BioNetworks Inc. Reports First Quarter Results for Fiscal Year 2017
for the Quarter ended 30 September 2016, in US dollars
Oct 07, 2016 08:12 pm ET
Epicore BioNetworks Inc. Reports Results for Fiscal Year 2016
For the year ended 30 June 2016, in US dollars
Oct 07, 2016 08:12 pm ET
Sep 28, 2016 05:30 pm ET
Epicore BioNetworks Inc. Announces Corporate Actions
EASTAMPTON, NJ, Sept. 28, 2016 /PRNewswire/ - Epicore BioNetworks Inc. is pleased to announce that a new director has joined the board, effective September 6, 2016. The Board welcomes Mr. Donald R. Siemens of Langley, B.C., Canada. Mr. Siemens holds a bachelor's degree from the University of British Colombia and has over 40 years' experience as a chartered accountant. He has held partnership positions with major accounting firms, senior executive positions in industry and experience as a self-employed financial services executive. The Board expects that his knowledge and experience will b
Sep 28, 2016 05:30 pm ET
Epicore BioNetworks Inc. Announces Corporate Actions
EASTAMPTON, NJ, Sept. 28, 2016 /CNW/ - Epicore BioNetworks Inc. is pleased to announce that a new director has joined the board, effective September 6, 2016. The Board welcomes Mr. Donald R. Siemens of Langley, B.C., Canada. Mr. Siemens holds a bachelor's degree from the University of British Colombia and has over 40 years' experience as a chartered accountant. He has held partnership positions with major accounting firms, senior executive positions in industry and experience as a self-employed financial services executive. The Board expects that his knowledge and experience will be of gr
Jun 16, 2016 05:30 pm ET
Jun 16, 2016 05:30 pm ET
Epicore BioNetworks Inc. Announces Corporate Actions
EASTAMPTON, NJ, June 16, 2016 /PRNewswire/ - Epicore BioNetworks Inc. announces the retirement of Mr. Philip A.D. Secretan and Mr. Fred N. Boulos as directors of the corporation. Both have served the Board faithfully and diligently for a combined 19 years. Their support and guidance helped Epicore evolve from a struggling startup to a successful enterprise. During their tenure, the Company has seen sales increase three fold, has been profitable in every quarter of operation and has grown to become a significant supplier to the world aquaculture industry. They leave the Company on solid f
Jun 09, 2016 05:30 pm ET
Jun 09, 2016 05:30 pm ET
May 10, 2016 05:30 pm ET
Epicore BioNetworks Inc. Reports Third Quarter Results for Fiscal Year 2016
For the Quarter ended 31 March 2016, in US dollars
May 10, 2016 05:30 pm ET
Feb 23, 2016 04:35 pm ET
Feb 23, 2016 04:35 pm ET
Epicore BioNetworks Inc. Reports Second Quarter Results for Fiscal Year 2016
For the Quarter ended 31 December 2015, in US dollars
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.